Amaç: Hidradenitis süpürativa (HS) veya akne inversa, çoğunlukla puberte sonrası ortaya çıkan ağrılı, derin yerleşimli, iltihaplı lezyonlarla karakterize kronik, inflamatuar, tekrarlayıcı bir deri hastalığıdır. Aksiller, inguinal ve anogenital bölgeler gibi vücudun apokrin bezlerden zengin bölgelerinde daha sık görülür. Çalışmamızda, dermatoloji polikliniğine başvuran HS tanılı ve ilk defa HS tanısı alan hastaların klinik ve sosyodemografik özelliklerini değerlendirdik. Gereç ve Yöntemler: Çalışmaya, dermatoloji ana bilim dalı polikliniğine başvuran HS tanılı ve ilk defa HS tanısı alan 50 hasta dâhil edildi. Çalışmaya dâhil edilen hastaların sosyodemografik özellikleri ve klinik bulguları kaydedildi. HS tanı kriterlerini karşılayan tüm hastalar çalışmaya dâhil edildi. Bulgular: HS ortalama başlangıç yaşı 22,52 yıl olup, erkeklerde daha ileri yaşlardaydı (p=0,001). HS tanısında ortalama gecikme süresi 73,66 ay olup, erkeklerde daha kısaydı (p=0,003). Hastaların %68'i fazla kilolu, obez ve morbid obez kategorisindeydi. Hastaların %72'sinde sigara öyküsü vardı. Hasta yoğunluğu orta ve şiddetli Hurley evrelerinde daha fazlaydı (evre II %48 ve evre III %32). En sık aksiller bölge (%90), inguinal bölge (%70) ve meme arası-altı bölgesi (%46) etkilenmişti. Erkeklerde aksiller ve atipik yerleşim bölgeleri, kadınlarda ise meme arası ve altı bölgesi yerleşimi anlamlıydı (p<0,05). Sigara öyküsü, yerleşim yerinin aksiller, inguinal ve gluteal bölge olması, toplam etkilenen bölge sayısı, foliküler oklüzyon bileşenlerinin eşlik etmesi ile hastalık şiddeti ilişkiliydi (p<0,05). Sonuç: Çalışmamızda hasta sayısı sınırlı olsa da ülkemiz HS epidemiyolojisine de katkıda bulunacaktır. Elde ettiğimiz veriler; ülkemiz ve diğer ülke verilerine benzemekle beraber birtakım farklılıklar göstermektedir. Bu da HS etiyopatogenezinde genetik ve etnik faktörlerin, sigara ve beslenme alışkanlıklarının rolü olabileceğini düşündürmektedir.
Anahtar Kelimeler: Epidemiyoloji; hidradenitis süpürativa; Hurley evrelemesi; klinik özellikler; sosyodemografik özellikler
Objective: Hidradenitis suppurativa (HS) or acne inversa is a chronic, inflammatory, recurrent skin disease characterized by painful, deeply located, inflammatory lesions that occur mostly after puberty. It is more common in areas of the body rich in apocrine glands, such as the axilla, inguinal and anogenital regions. In our study, we evaluated the clinical and sociodemographic characteristics of patients diagnosed with HS and diagnosed with HS for the first time, who applied to the dermatology policlinic. Material and Methods: Fifty patients diagnosed with HS and diagnosed with HS for the first time, who applied to the dermatology department polyclinic were included in the study. Sociodemographic characteristics and clinical findings of the patients included in the study were recorded. All patients who met the diagnostic criteria for HS were included in the study. Results: The mean age of onset of HS was 22.52 years and it was more advanced in males (p=0.001). The mean delay time in the diagnosis of HS was 73.66 months and it was shorter in men (p=0.003). 68% of the patients were in the overweight, obese and morbidly obese categories. 72% of the patients had a history of smoking. In our study, the patient density was higher in moderate and severe Hurley stages (Hurley stage II 48% and stage III 32%). The axillary region (90%) and inguinal region (70%) and interbreast and submammary region (46%) were most frequently affected. In men, axillary and atypical localization regions were significant, while in women, the location between and below the breasts was significant (p<0.05). The severity of the disease was associated with smoking history, localization in the axilla, inguinal and gulteal region, total number of affected areas, and accompanying follicular occlusion components (p<0.05). Conclusion: Although the number of patients in our study was limited, it will also contribute to the epidemiology of HS in our country. The data we obtained; although it is similar to the data of our country and other countries, it shows some differences. This suggests that genetic and ethnic factors, smoking and dietary habits may play a role in the etiopathogenesis of HS.
Keywords: Epidemiology; hidradenitis suppurativa; Hurley staging; clinical features; sociodemographic features
- Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-44. [Crossref] [PubMed]
- von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14(5):389-92. [Crossref] [PubMed]
- Sung S, Kimball AB. Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69(5):818-9. [Crossref] [PubMed]
- Vinding GR, Miller IM, Zarchi K, Ibler KS, Ellervik C, Jemec GB. The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170(4):884-9. [Crossref] [PubMed]
- van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol. 2010;162(1):195-7. [Crossref] [PubMed]
- Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J. 2013;19(6):18558. [Crossref] [PubMed]
- Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021;10(8):2094. [Crossref] [PubMed] [PMC]
- Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105-15. [Crossref] [PubMed] [PMC]
- Vinkel C, Thomsen SF. Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol. 2018;11(10):17-23. [PubMed] [PMC]
- Pink A, Anzengruber F, Navarini AA. Acne and hidradenitis suppurativa. Br J Dermatol. 2018;178(3):619-31. [Crossref] [PubMed]
- Schneider-Burrus S, Jost A, Peters EMJ, Witte-Haendel E, Sterry W, Sabat R. Association of hidradenitis suppurativa with body image. JAMA Dermatol. 2018;154(4):447-51. [Crossref] [PubMed] [PMC]
- Revuz JE, Jemec GB. Diagnosing hidradenitis suppurativa. Dermatol Clin. 2016;34(1):1-5. [Crossref] [PubMed]
- Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460-7. [Crossref] [PubMed]
- Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596-601. [Crossref] [PubMed]
- Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760-4. [Crossref] [PubMed] [PMC]
- Choi E, Chandran NS. Rethinking the female predominance in hidradenitis suppurativa. Int J Dermatol. 2019;58(3):e57-8. [Crossref] [PubMed]
- Özkur E, Karadağ AS, Üstüner P, Aksoy B, Eşme P, Çalışkan E, et al. Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. Clin Exp Dermatol. 2021;46(3):532-40. [Crossref] [PubMed]
- Vural S, Gündoğdu M, Akay BN, Boyvat A, Erdem C, Koçyiğit P, et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy. Dermatol Ther. 2019;32(5):e13003. [Crossref] [PubMed]
- Yüksel M, Basım P. Demographic and clinical features of hidradenitis suppurativa in Turkey. J Cutan Med Surg. 2020;24(1):55-9. [Crossref] [PubMed]
- Chandran NS, Lee JH, Kurokawa I. Hidradenitis suppurativa in South-East Asia and East Asia. Exp Dermatol. 2021;30 Suppl 1:23-6. [Crossref] [PubMed]
- Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546-9. [Crossref] [PubMed]
- Von Der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol. 2000;142(5):947-53. [Crossref] [PubMed]
- Yang JH, Moon J, Kye YC, Kim KJ, Kim MN, Ro YS, et al; Korean Society for Acne Research. Demographic and clinical features of hidradenitis suppurativa in Korea. J Dermatol. 2018;45(12):1389-95. [Crossref] [PubMed]
- Kurokawa I, Hayashi N; Japan Acne Research Society. Questionnaire surveillance of hidradenitis suppurativa in Japan. J Dermatol. 2015;42(7):747-9. [Crossref] [PubMed]
- Hoffman LK, Ghias MH, Lowes MA. Pathophysiology of hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36(2):47-54. [Crossref] [PubMed]
- Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97-103. [Crossref] [PubMed] [PMC]
- Acharya P, Mathur M. Hidradenitis suppurativa and smoking: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(4):1006-11. [Crossref] [PubMed]
- Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S27-35. [Crossref] [PubMed]
- Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GB. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171(4):819-24. [Crossref] [PubMed]
- Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61(1):51-7. [Crossref] [PubMed]
- Vankeviciute RA, Polozovaite B, Trapikas J, Raudonis T, Grigaitiene J, Bylaite-Bucinskiene M. A 12-year experience of hidradenitis suppurativa management. Adv Skin Wound Care. 2019;32(1):1-7. [Crossref] [PubMed]
- Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol. 2010;90(3):264-8. [Crossref] [PubMed]
- Kimball AB, Sundaram M, Gauthier G, Guérin A, Pivneva I, Singh R, et al. The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis. Dermatol Ther (Heidelb). 2018;8(4):557-69. [Crossref] [PubMed] [PMC]
- Wertenteil S, Strunk A, Garg A. Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa. J Am Acad Dermatol. 2019;80(5):1308-13. [Crossref] [PubMed]
- Omine T, Miyagi T, Hayashi K, Yamaguchi S, Takahashi K. Clinical characteristics of hidradenitis suppurativa patients in Okinawa, Japan: differences between East Asia and Western countries. J Dermatol. 2020;47(8):855-62. [Crossref] [PubMed]
.: İşlem Listesi